Advancement in the management of Von Hippel Lindau (VHL) Disease: A Comprehensive Educational Program on hypoxia-inducible factor-2 alpha inhibitor (HIF-2a)
DÉTAILS DE L’ACTIVITÉ
CRÉDITS
Chair: Simon Tanguay
Speakers: Shereen Ezzat & Maryam Soleimani
OBJECTIVES
By participating in this learning program, healthcare providers can expect to:
- Discuss the mechanism of action of HIF-2α inhibitors in suppressing tumor growth in VHL-related tumors.
- Examine the clinical efficacy and safety profile of HIF-2α inhibitors and impact on clinical practice.
- Explore strategies for early identification and management of side effects associated with HIF-2α inhibitors, based on evidence-based medicine and lessons learned from real-world experience.
Simultaneous interpretation from English to French will be available